U.S. Banks Stock News

Dividend hike and full year results put International Bancshares in focus International Bancshares (IBOC) is back on investor radars after the board approved a $0.73 per share cash dividend, a 4.3% increase, alongside the release of full year 2025 financial results. See our latest analysis for International Bancshares. At a share price of $68.26, International Bancshares has seen a 1-day share price return of 0.72% and a 1-month share price return of 2.60%, while the 1-year total shareholder...

This article explores whether Liberty Energy's share price still reflects good value, or if the easier gains may already have occurred, by considering what the current price might be implying about the company. Liberty Energy closed at US$27.67, with a 4.1% decline over the last 7 days, a 3.2% gain over 30 days, a 46.6% return year to date, and a 169.7% return over the past year. Recent coverage has focused on Liberty Energy as part of broader discussions around US energy services companies...

Versigent PLC (NYSE:VGNT) has completed its spin-off from Aptiv’s Electrical Distribution Systems business, forming an independent publicly listed company. The separation was accompanied by a broad refresh of the board and executive team, including new CEO and CFO appointments and restructured board committees. Versigent converted from a limited company to a public limited company, adopted a new name and bylaws, and was added to several major equity benchmarks. Versigent now trades as...

MoonLake Immunotherapeutics recently reported long-term Week 40 Phase 3 VELA-1 and VELA-2 data for sonelokimab in moderate-to-severe hidradenitis suppurativa, showing strong efficacy on HiSCR75 and quality-of-life endpoints with a stable safety profile. An interesting feature of these results is the use of a higher HiSCR75 threshold as the primary endpoint, positioning sonelokimab against existing IL-17A and IL-17A/F therapies on a more stringent efficacy measure. We’ll now examine how...

Worthington Steel (WS) is back in focus after reporting third quarter results that showed higher sales but lower quarterly net income compared with a year earlier, along with higher nine-month earnings and a reaffirmed quarterly dividend. See our latest analysis for Worthington Steel. The latest results and dividend decision come after a mixed price pattern, with a 5.05% 7 day share price return, a 19.61% 30 day share price decline, and a 31.76% 1 year total shareholder return, suggesting...

In March 2026, Gilat Satellite Networks’ Gilat DataPath unit reported receiving about US$6,000,000 in new orders over six months to continue providing field and technical services that support U.S. Army global communications operations under the GTACS II contract vehicle. This extension deepens Gilat’s multi-year role in mission-critical U.S. defense communications, underscoring the company’s position as a trusted supplier of resilient connectivity for military operations. We’ll now examine...

Recent commentary highlights how PDF Solutions has been benefiting from AI-led digital transformation, as customers increasingly adopt its cloud-enabled software, unified data platforms, and real-time analytics to manage more complex semiconductor manufacturing. An important insight is that rising investments in 3D manufacturing, AI-driven collaboration, and geographic diversification are amplifying demand for PDF Solutions’ consulting, research, cybersecurity, and compliance-focused...

In late March 2026, Hudson Technologies announced a licensing agreement with Solstice Advanced Materials to reclaim and resell Solstice’s patented lower-GWP HFO refrigerant blends R-448A and R-449A across the United States and Canada under AIM Act-compliant applications in the supermarket segment. This agreement gives Solstice broader access to the refrigeration retrofit market while aligning its technology with tightening environmental regulations on higher-GWP refrigerants. Next, we’ll...

Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US based fill finish site. See our latest analysis for Scholar Rock Holding. The BLA resubmission appears to have kept attention on Scholar Rock, with a 7 day share price return of 13.3% and an 18.16% 90 day share price return. The 1 year total shareholder return of 87.44% points to strong momentum...

AI is starting to reshape how healthcare is delivered, from spotting disease earlier to tailoring treatments and cutting wasted time in hospitals, just as energy driven inflation and higher yields keep pressure on costs worldwide. For investors, that mix of structural healthcare demand and AI driven efficiency tools offers exposure to a theme that is less tied to short term swings in consumer spending or manufacturing cycles. This article walks through 3 stocks from our Transformative AI...

Recent analysis of past performance shows that Service Corporation International has not increased the number of funeral services performed over the last two years, while also reporting weaker free cash flow margins and a declining return on invested capital compared with sector expectations. This combination of stagnant service volumes and deteriorating profitability metrics suggests the company may be contending with demand constraints and limited high-return reinvestment...

Acuity (AYI) is back in focus after its second quarter 2026 earnings, where adjusted earnings per share came in ahead of expectations while revenue lagged forecasts, highlighting contrasting trends across its Lighting and Intelligent Spaces businesses. See our latest analysis for Acuity. The share price reaction has been mixed, with a 1 day share price return of 1.06% after earnings but a 90 day share price return representing a 28.55% decline. However, the 3 year total shareholder return of...

Xeris Biopharma Holdings (XERS) drew fresh investor attention after reporting fourth quarter 2025 earnings per share of US$0.06 on revenue of US$85.8 million, both above prior projections and supported by a reiteration of positive analyst views. See our latest analysis for Xeris Biopharma Holdings. At a share price of US$6.05, Xeris Biopharma’s recent 8.04% 7 day share price return and 4.13% 30 day share price return contrast with a 17.69% decline year to date. At the same time, the 37.19% 1...

Olin Corporation recently received an upgrade from Wells Fargo, with the firm citing expectations of stronger margins in its electrochemical operations supported by higher caustic soda prices and stable North American natural gas costs. This shift in analyst view highlights how Olin’s earnings outlook is increasingly being tied to both its cost position and evolving global chemical pricing shaped by geopolitical tensions. We’ll now examine how this margin-focused upgrade from Wells Fargo...

In early April 2026, Prestige Consumer Healthcare faced pressure after regulatory scrutiny, including FTC concerns over industry consolidation and a federal healthcare fraud crackdown, weighed on sentiment around its over-the-counter product portfolio. Beyond the immediate regulatory overhang, the episode highlights how sector-wide oversight can quickly reshape market perceptions of risk around even established healthcare brands. Against this backdrop of intensified regulatory attention,...

EverCommerce recently reported its Q4 results and issued guidance for Q1 and the 2026 fiscal year, prompting a strong reaction against a backdrop of geopolitical uncertainty. The fresh guidance has sharpened investor focus on how EverCommerce’s execution in its core SaaS and payments offerings may align with earlier expectations. Now we’ll explore how EverCommerce’s latest earnings and guidance update could reshape its investment narrative built around SaaS and payments. AI is about to...

In the fourth quarter, SG Americas Securities LLC sharply increased its stake in Liberty Broadband Corporation to 81,610 shares, a very large percentage rise that underscores growing institutional participation. This surge in ownership highlights how Liberty Broadband’s exposure to Charter Communications continues to act as a focal point for institutional interest and portfolio positioning. Against this backdrop of heavier institutional involvement, we’ll now explore how increased Wall...

Healthcare Services Group (HCSG) has been drawing attention after a strong 1 year total return of 85.35%, in contrast with recent share price softness over the past month and past 3 months. See our latest analysis for Healthcare Services Group. Recent trading has cooled after that strong 1 year total shareholder return of 85.35%. The 30 day share price return of an 11.14% decline points to fading near term momentum, even as the longer term total shareholder return profile remains positive...

Global Business Travel Group (GBTG) is back on investor radar after options activity showed elevated implied volatility in certain call contracts. This coincides with UBS reaffirming its rating while trimming expectations and the company maintaining its 2026 guidance. See our latest analysis for Global Business Travel Group. At a share price of US$5.56, Global Business Travel Group has seen short term momentum soften, with a 7 day share price return of 2.96% set against a 90 day share price...

In early April 2026, Albany International’s Albany Engineered Composites segment was recognized by EHS Today as one of America’s Safest Companies, highlighting its certified environmental, health and safety systems across commercial and military aerospace operations. A few days earlier, Albany International reported quarterly revenue above analyst expectations but weaker EBITDA and EPS, and began a formal review of its aerospace structures assembly business and Salt Lake City site, signaling...

Tarsus Pharmaceuticals has already dosed the first participant in its Phase 2 Calliope trial of TP-05, an oral lotilaner-based therapy being tested in about 700 at-risk adults across U.S. Lyme-endemic regions, where no FDA-approved drug prophylaxis currently exists. This move extends Tarsus beyond eye-care into infectious disease prevention, targeting a large U.S. population considered at moderate to high risk for Lyme disease. We’ll now examine how TP-05’s Phase 2 progress, as a potential...

Cboe Global Markets plans to introduce 24-hour, 5-days-per-week trading for U.S. equities on its EDGX exchange, pending regulatory review. The move would extend U.S. stock trading to an around-the-clock schedule on weekdays, aligning more closely with global trading hours. The initiative is aimed at giving investors continuous access to U.S. equities and could influence liquidity patterns and competition across trading venues. Cboe Global Markets (BATS:CBOE) is pursuing this expanded...

In March 2026, Fidelity National Financial, Inc. appointed Jeffrey Heighton as President of Enterprise Solutions – Agency to work with title agents on growth, financial performance, and technology-driven operational scale. This hire expands FNF’s consultative model for its agency network, deepening support around revenue strategy, expense management, and back-office optimization. Next, we’ll examine how AI-driven downgrades tied to weakening cash flow and profitability pressures may...

Over the last 7 days, the United States market has risen by 3.5%, contributing to a remarkable 31% increase over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, identifying stocks that are potentially undervalued can offer investors opportunities to capitalize on price discrepancies relative to their intrinsic value.